Ohsu Knight Cancer Institute
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Evaluating the Human Papillomavirus Self-Collection Experience in Individuals Who Have Experienced Sexual Trauma
Completed
- Conditions
- Human Papillomavirus InfectionCervical Carcinoma
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT05458869
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
The Use of "Smart" Body-Weight Scales for Weight and Nutritional Monitoring in Patients with Head and Neck Cancer Undergoing Radiation Therapy
Not Applicable
Terminated
- Conditions
- Head and Neck Squamous Cell CarcinomaMalignant Head and Neck Neoplasm
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 2
- Registration Number
- NCT05457478
- Locations
- πΊπΈ
Mid-Atlantic Permanente Medical Group, Rockville, Maryland, United States
πΊπΈOHSU Knight Cancer Institute, Portland, Oregon, United States
A Surgical Procedure (Total Pancreatectomy) With a Transplant Procedure (Islet Cell Autotransplantation) for the Treatment of Chronic Pancreatitis and Benign Pancreatic Tumors
Phase 1
Not yet recruiting
- Conditions
- Chronic PancreatitisRecurrent Acute PancreatitisBenign Pancreatic Neoplasm
- First Posted Date
- 2022-07-12
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT05453851
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Improving Decision-Making Encounters in Lung Cancer Using a Low-Literacy Conversation Tool
Not Applicable
Recruiting
- Conditions
- Lung Carcinoma
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 300
- Registration Number
- NCT05407168
- Locations
- πΊπΈ
Hillsboro Medical Center, Hillsboro, Oregon, United States
πΊπΈAdventist Health Portland, Portland, Oregon, United States
πΊπΈOHSU Knight Cancer Institute, Portland, Oregon, United States
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
Phase 1
Suspended
- Conditions
- Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 12
- Registration Number
- NCT05396859
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian Cancer
Early Phase 1
Withdrawn
- Conditions
- Advanced Fallopian Tube CarcinomaAdvanced Ovarian CarcinomaAdvanced Primary Peritoneal CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaStage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8
- Interventions
- Drug: Wee1 Inhibitor ZN-c3
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05368506
Feasibility of OmnEcoil System for Integrated Endorectal MRI and Transrectal MRI-Targeted Biopsy of the Prostate
Not Applicable
Suspended
- Conditions
- Prostate Carcinoma
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT05362032
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
Phase 2
Withdrawn
- Conditions
- BCLC Stage B Hepatocellular CarcinomaUnresectable Hepatocellular CarcinomaRecurrent Hepatocellular CarcinomaLocally Advanced Hepatocellular CarcinomaBCLC Stage C Hepatocellular Carcinoma
- Interventions
- Biological: AtezolizumabProcedure: BiopsyRadiation: Yttrium Y 90 Glass Microspheres
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-12-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05327738
At-Home Dermoscopy Artificial Intelligence
Not Applicable
Terminated
- Conditions
- Malignant Skin Neoplasm
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT05321784
- Locations
- πΊπΈ
OHSU Knight Cancer Institute, Portland, Oregon, United States
SMMART Adaptive Clinical Treatment (ACT) Trial
Early Phase 1
Withdrawn
- Conditions
- Advanced Breast CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Stage II Pancreatic Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Advanced Prostate CarcinomaRecurrent Adult Soft Tissue SarcomaRecurrent Breast CarcinomaStage IV Ovarian Cancer AJCC v8Advanced Malignant Solid NeoplasmAdvanced Ovarian Carcinoma
- Interventions
- Biological: AtezolizumabBiological: BevacizumabProcedure: BiopsyProcedure: Biospecimen CollectionBiological: Hyaluronidase-zzxf/Pertuzumab/TrastuzumabBiological: PertuzumabOther: Quality-of-Life AssessmentBiological: TrastuzumabBiological: Trastuzumab Emtansine
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- OHSU Knight Cancer Institute
- Registration Number
- NCT05238831